Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin radioimmunotherapy versus autologous stem cell transplantation in relapsed follicular lymphoma
2012-000251-14Phase 3Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Apr 2012
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibritumomab tiuxetan in follicular lymphoma (FL) (2 arms), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Progression-free survival from randomization. Started Apr 2012; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2012-000251-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000251-14.